期刊
JOURNAL OF BIOMOLECULAR SCREENING
卷 18, 期 9, 页码 1110-1120出版社
SAGE PUBLICATIONS INC
DOI: 10.1177/1087057113493117
关键词
pre-mRNA splicing; spliceosome; RT-qPCR; inhibitor; high-throughput assay
资金
- University of California Cancer Research Coordinating Committee
- National Institutes of Health [R01CA136762]
- NIH [1S10RR022455]
- California Institute for Quantitative Biosciences (QB3)
- US Department of State
The spliceosome is the macromolecular machine responsible for pre-mRNA splicing, an essential step in eukaryotic gene expression. During splicing, myriad subunits join and leave the spliceosome as it works on the pre-mRNA substrate. Strikingly, there are very few small molecules known to interact with the spliceosome. Splicing inhibitors are needed to capture transient spliceosome conformations and probe important functional components. Such compounds may also have chemotherapeutic applications, as links between splicing and cancer are increasingly uncovered. To identify new splicing inhibitors, we developed a high-throughput assay for in vitro splicing using a reverse transcription followed by quantitative PCR readout. In a pilot screen of 3080 compounds, we identified three small molecules that inhibit splicing in HeLa extract by interfering with different stages of human spliceosome assembly. Two of the compounds similarly affect spliceosomes in yeast extracts, suggesting selective targeting of conserved components. By examining related molecules, we identified chemical features required for the activity of two of the splicing inhibitors. In addition to verifying our assay procedure and paving the way to larger screens, these studies establish new compounds as chemical probes for investigating the splicing machinery.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据